Misplaced Pages

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Matrix metalloproteinase inhibitor" – news · newspapers · books · scholar · JSTOR (December 2013) (Learn how and when to remove this message)

A matrix metalloproteinase inhibitor (INN stem –mastat) inhibits matrix metalloproteinases. Because they inhibit cell migration, they have antiangiogenic effects. They are endogenous or exogenous.

The most notorious endogenous metalloproteinases are tissue inhibitors of metalloproteinases, followed by cartilage-derived angiogenesis inhibitors.

Exogenous matrix metalloproteinase inhibitors were developed as anticancer drugs. Examples include:

• Batimastat
• Cipemastat
• Ilomastat
• Marimastat
• Prinomastat
• Tanomastat

Metalloproteinase inhibitors are found in numerous marine organisms, including fish, cephalopods, mollusks, algae and bacteria.

See also

• Drug discovery and development of MMP inhibitors

References

1. "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. Retrieved 5 November 2016.
2. Coussens, L. M. (2002). "Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations". Science. 295 (5564): 2387–2392. Bibcode:2002Sci...295.2387C. doi:10.1126/science.1067100. ISSN 0036-8075. PMID 11923519. S2CID 19944201.
3. Noel Vinay Thomas; Se Kwon Kim (2010). "Metalloproteinase Inhibitors Stts and Scope from Marine Organisms". Biochemistry Research International. 2010: 845975. doi:10.1155/2010/845975. PMC 3004377. PMID 21197102.

This biochemistry article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Angiology
• Biochemistry
• Matrix metalloproteinase inhibitors
• Biochemistry stubs